Literature DB >> 6441668

Detection of antilymphocyte antibodies in patients with scleroderma using three different techniques.

M T Labro, A Perianin, M F Kahn.   

Abstract

The occurrence of antilymphocyte antibodies (AL-Ab) was investigated in the sera of 28 patients with scleroderma. By indirect immunofluorescence, we found these Ab in 53% of the sera. Inhibition of E rosette formation and lymphocytotoxicity revealed these Ab in 42% and 14% of the sera respectively. Most of the Ab (93%) reacted at 0 degrees C. These AL-Ab can be separated into several groups depending on their inhibitory activity on the lymphocyte membrane. In some cases, the receptor seems similar to that of sheep red blood cells. The study of the clinical features of the patients showed few differences between the groups with and those without Al-Ab. It must be noted that all the patients with the CREST syndrome (6 cases) possessed Al-Ab.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6441668     DOI: 10.1007/bf02031265

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN: 0770-3198            Impact factor:   2.980


  21 in total

1.  Identification of a nuclear protein (Scl-70) as a unique target of human antinuclear antibodies in scleroderma.

Authors:  A S Douvas; M Achten; E M Tan
Journal:  J Biol Chem       Date:  1979-10-25       Impact factor: 5.157

2.  Antibodies eluted from lymphoid cell membrane. Occurrence in certain varieties of scleroderma.

Authors:  R H Cormane; F Hamerlinck; E Nunzi
Journal:  Arch Dermatol       Date:  1979-06

3.  Does OKT3 monoclonal antibody react with an antigen-recognition structure on human T cells?

Authors:  T W Chang; P C Kung; S P Gingras; G Goldstein
Journal:  Proc Natl Acad Sci U S A       Date:  1981-03       Impact factor: 11.205

4.  Distinctive functional characteristics of human "T" lymphocytes defined by E rosetting or a monoclonal anti-T cell antibody.

Authors:  P C Beverley; R E Callard
Journal:  Eur J Immunol       Date:  1981-04       Impact factor: 5.532

5.  Lymphocytotoxic and phagocytotoxic activity in progressive systemic sclerosis.

Authors:  W Pruzanski; P Lee; A Willshire; D Gladman; E C Keystone
Journal:  J Rheumatol       Date:  1983-02       Impact factor: 4.666

6.  Lymphocyte subpopulations and reactivity to mitogens in patients with scleroderma.

Authors:  M Baron; E C Keystone; D D Gladman; P Lee; L Poplonski
Journal:  Clin Exp Immunol       Date:  1981-10       Impact factor: 4.330

7.  Autoantibody to centromere (kinetochore) in scleroderma sera.

Authors:  Y Moroi; C Peebles; M J Fritzler; J Steigerwald; E M Tan
Journal:  Proc Natl Acad Sci U S A       Date:  1980-03       Impact factor: 11.205

8.  The CREST syndrome: a distinct serologic entity with anticentromere antibodies.

Authors:  M J Fritzler; T D Kinsella
Journal:  Am J Med       Date:  1980-10       Impact factor: 4.965

9.  Endothelial injury in scleroderma. A protease mechanism.

Authors:  M B Kahaleh; E C Leroy
Journal:  J Lab Clin Med       Date:  1983-04

10.  Serum effects of mitogenic reactivity in subjects with systemic lupus erythematosus, rheumatoid arthritis and scleroderma. Technical considerations and lack of correlation with anti-lymphocyte antibodies.

Authors:  D A Horwitz; M A Garrett; A H Craig
Journal:  Clin Exp Immunol       Date:  1977-01       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.